CAMBRIDGE, Mass.--(BUSINESS WIRE)--Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB).The company has introduced a new corporate identity and logo that reflect both its ...

Biogen, for its part, could probably pick up this intriguing asset for less than $700 million -- given Cassava's tiny market cap of $255 million and weak financial position. 3.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch ...

BOSTON (MarketWatch) -- Biogen Idec's general counsel, who sold company stock on the day it reported problems with its Tysabri drug last month, resigned late Wednesday, the company said. Biogen ...